Immunic to Showcase Innovations in Biotechnology at Upcoming Conferences This May
Immunic's Upcoming Conference Participation in May 2025
Immunic, Inc. (Nasdaq: IMUX), a prominent name in biotechnology, is gearing up for a significant presence at major scientific and industry events this May. The company specializes in developing oral therapies that address chronic inflammatory and autoimmune diseases. Their involvement in key conferences demonstrates their commitment to sharing cutting-edge research and engaging with leading experts in the field.
Participation in Key Conferences
1. Digestive Disease Week (DDW)
Dates: May 3-6, 2025
Location: San Diego, CA
At DDW, Immunic will showcase two important abstracts related to their phase 1/1b clinical trial of IMU-856. This innovative oral therapy focuses on patients with celiac disease, a condition that negatively impacts the digestive system.
- Poster 1:
- Title: IMU-856 vs. Placebo Efficacy Effects in Celiac Disease Patients Are Independent of Q-MARSH Scale at Baseline
- Abstract ID: 4216653
- Presenter: Dr. Indira Pichetto Olanda, Associate Medical Manager
- Session: Enteropathies – Celiac, Gluten-Related and Environmental
- Date/Time: May 6, 2025 / 12:30 PM – 1:30 PM PDT
- Poster 2:
- Title: Influence of Gut Epithelial Condition on the Pharmacokinetic Properties of IMU-856
- Abstract ID: 4219364
- Presenter: Dr. Jacques Arend, Head of Clinical Pharmacology
- Session: Enteropathies – Celiac, Gluten Related and Environmental
- Date/Time: May 6, 2025 / 12:30 PM – 1:30 PM PDT
2. Clinical Trial Supply Forum 2025
Dates: May 13-15, 2025
Location: Brussels, Belgium
Immunic will also be actively participating at the Clinical Trial Supply Forum where Kimi Oanh Le, the Head of Clinical Trial Supply at Immunic, will deliver insights on managing supply chain challenges in the MENA region. Her case study will address specific hurdles faced in clinical trials and highlight Immunic’s approaches to overcoming these barriers.
- Presentation Type: Case Study
- Title: Immunic Therapeutics Supply Chain Challenges Working Across MENA
- Date/Time: May 14, 2025 / 10:40 AM CEST
3. Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2025
Dates: May 28-31, 2025
Location: Phoenix, AZ
Immunic's management, medical, and preclinical teams will attend this important annual event, facilitating discussions and sharing knowledge with industry peers. They will be featuring a poster presentation of preclinical data concerning vidofludimus calcium (IMU-838), their lead asset.
- Poster Title: In Preclinical Models, Vidofludimus Calcium Exhibits Potential Neuroprotective Effects in Multiple Sclerosis by Modulating Nurr1
- Presenter: Dr. Amelie Schreieck, Senior Manager Biomarker Development
- Abstract ID: 10271
- Date/Time: May 29, 2025 / 5:00 PM – 7:00 PM MST
- Booth: #911
About Immunic, Inc.
Immunic, Inc. is at the forefront of developing transformative oral therapies for chronic inflammatory and autoimmune diseases. Their flagship program, vidofludimus calcium (IMU-838) is currently undergoing phase 3 clinical trials, focusing on treating relapsing multiple sclerosis, with promising results from previous trials. This therapy is designed to provide neuroprotective effects while combating inflammation and viral responses, setting a new standard in multiple sclerosis treatment protocols. Additionally, IMU-856 aims to restore intestinal barrier function, exploring applications beyond celiac disease to include inflammatory bowel disease and other gastrointestinal conditions.
As Immunic continues to innovate, their presence at these conferences not only underscores their advancements but also fosters collaboration and discussion within the scientific community. Attendees can find more detailed information about their presentations on Immunic's official website under the events section.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.